Its safety in individuals over 75 years of age is not established
Hasegawa, K., Miwa, S., Tsutsumiuchi, K
Mankertz, J., Hillenbrand, B., Tavalali, S., Huber, O., Fromm, M
The reality of oral administration for musculoskeletal indications is straightforward: the peptide disperses through the digestive system before it reaches the injury site, and what arrives at a tendon or joint after that journey is a fraction of what a subcutaneous injection placed near the tissue delivers
PEU patients are likely to experience vitamin B6 deficiencies
Anecdotally I do notice that a lot of my patients with both benign and malignant tumors do have very high igf ones over 300